New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - iloprost 0.1 mg/ml equivalent to iloprost trometamol 0.134 mg/ml;   - concentrate for infusion - 0.05 mg/0.5ml - active: iloprost 0.1 mg/ml equivalent to iloprost trometamol 0.134 mg/ml   excipient: ethanol as 96% v/v hydrochloric acid as 1m hcl nitrogen sodium chloride trometamol water for injection - treatment of patients with severe peripheral arterial occlusive disease (poad), particularly those at risk of amputation and in whom surgery or angioplasty is not possible. treatment of advanced thromboangitis obliterans (buerger's disease) with critical limb ischaemia in cases where revascularisation is not indicated. treatment of patients with severe disabling raynaud's phenomenon unresponsive to other therapies. treatment of moderate or severe primary and secondary pulmonary hypertension such as new york heart association functional classes iii and iv.

New Zealand - English - Medsafe (Medicines Safety Authority)

biomed limited - hetastarch 10%{relative} (pentastarch) - solution for injection - 10% w/v - active: hetastarch 10%{relative} (pentastarch) excipient: sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

biomed limited - hetastarch 6%{relative} - solution for injection - 6 % - active: hetastarch 6%{relative} excipient: sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iloprost trometamol 134 µg/ml equivalent to 100 µg iloprost/ml;  ;   - solution for infusion - 50 mcg/0.5ml - active: iloprost trometamol 134 µg/ml equivalent to 100 µg iloprost/ml     excipient: ethanol hydrochloric acid sodium chloride trometamol water for injection - treatment of patients with severe peripheral arterial occlusive disease (paod) particularly those at risk of amputation and in whom surgery or angioplasty is not possible.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - suspension - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

tramadol hydrochloride bp 50mg

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorio farmaceutico s.i.t. - biperiden hydrochloride - tablet - 2 milligram(s) - tertiary amines; biperiden

Ireland - English - HPRA (Health Products Regulatory Authority)

niche generics limited - fluconazole - solution for infusion - 2 mg/ml

European Union - English - EMA (European Medicines Agency)

schering-plough europe - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - posaconazole sp is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole sp is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sykes vet (international) pty. ltd. - magnesium sulphate - parenteral liquid/solution/suspension - magnesium sulphate mineral-magnesium active 250.0 g/l - nutrition & metabolism